fig2
![The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities](https://image.oaes.cc/a506494c-1103-42df-878d-ff2cd23dbbde/cdr6008.fig.2.jpg)
Figure 2. Cellular pathways that can be targeted to overcome PARPi resistance in HRp tumors. ATM: Ataxia-telangiectasia mutated; ATR: ataxia telangiectasia and Rad3-related; CDK1: cyclin-dependent kinase 1; CDK2: cyclin-dependent kinase 2; CDK12: cyclin-dependent kinase 12; ERK: extracellular signal-regulated kinase; HDAC: histone deacetylases; MEK: MAPK/ERK kinase; PARP: poly (ADP-ribose) polymerases inhibitors; PI3K: phosphatidylinositol-3 kinase; RNApol: RNA polymerase; TOPBP1: DNA topoisomerase II binding protein 1.